Study type: Human research · Status: Evidence verified by machine against declared source
Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial
Frontiers in neurology · 2025
Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
This is an investigator-initiated, academic driven hospital-based, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE), phase IV parallel-group trial planned in Polish stroke units with access to rehabilitation wards.
Study design
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study scale
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Intervention or exposure
Intracerebral hemorrhage (ICH) accounts for 15% of strokes with high mortality and limited treatment options.
Comparator
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Outcomes examined
CLINCH is an investigator led, academic driven multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) phase IV pilot study evaluating cerebrolysin in primary lobar ICH.
Key findings
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.